Literature DB >> 16720724

FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor.

T Yamaguchi1, A Kurisaki, N Yamakawa, K Minakuchi, H Sugino.   

Abstract

The cytoplasmic immunophilin FKBP12, a 12 kDa FK506-binding protein, has been shown to act as an inhibitor for transforming growth factor-beta (TGF-beta) signaling. FKBP12 binds to the glycine- and serine-rich motif (GS motif) of the TGF-beta type I receptor, and functions as a secure switch to prevent the leaky signal. Upon stimulation with ligand, FKBP12 is released from the receptor to fully propagate the signal. We found that activin, a member of TGF-beta superfamily, also induced the dissociation of FKBP12 from the activin type I receptor (ALK4). However, we observed that the released FKBP12 associates again with the receptor a few hours later. FKBP12 also interacted with another inhibitory molecule of activin signal, Smad7, in an activin-dependent manner, and formed a complex with Smad7 on the type I receptor. FK506, a chemical ligand for FKBP12, which dissociates FKBP12 from the receptor, decreased the interaction between Smad7 and Smad ubiquitin regulatory factor 1 (Smurf1). FK506 also inhibited the ubiquitination of the type I receptor by Smurf1. These findings indicate a new inhibitory function of FKBP12 as an adaptor molecule for the Smad7-Smurf1 complex to regulate the duration of the activin signal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720724     DOI: 10.1677/jme.1.01966

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  25 in total

1.  Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease.

Authors:  K L Hippen; S C Merkel; D K Schirm; C Nelson; N C Tennis; J L Riley; C H June; J S Miller; J E Wagner; B R Blazar
Journal:  Am J Transplant       Date:  2011-05-12       Impact factor: 8.086

Review 2.  Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds.

Authors:  Bryan M Dunyak; Jason E Gestwicki
Journal:  J Med Chem       Date:  2016-07-25       Impact factor: 7.446

Review 3.  Post-translational regulation of TGF-β receptor and Smad signaling.

Authors:  Pinglong Xu; Jianming Liu; Rik Derynck
Journal:  FEBS Lett       Date:  2012-05-19       Impact factor: 4.124

4.  Smad7 is required for the development and function of the heart.

Authors:  Qian Chen; Hanying Chen; Dawei Zheng; Chenzhong Kuang; Hong Fang; Bingyu Zou; Wuqiang Zhu; Guixue Bu; Ting Jin; Zhenzhen Wang; Xin Zhang; Ju Chen; Loren J Field; Michael Rubart; Weinian Shou; Yan Chen
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

Review 5.  TGF-β Signaling from Receptors to Smads.

Authors:  Akiko Hata; Ye-Guang Chen
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

6.  When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Jay Groppe; Eileen M Shore
Journal:  Drug Discov Today Ther Strateg       Date:  2008

7.  Lysine conservation and context in TGFbeta and Wnt signaling suggest new targets and general themes for posttranslational modification.

Authors:  Charlotte E Konikoff; Robert G Wisotzkey; Stuart J Newfeld
Journal:  J Mol Evol       Date:  2008-09-17       Impact factor: 2.395

Review 8.  Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP).

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Bone       Date:  2008-05-28       Impact factor: 4.398

Review 9.  The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling.

Authors:  Frederick S Kaplan; Robert J Pignolo; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-06       Impact factor: 7.638

Review 10.  Informatics approaches to understanding TGFbeta pathway regulation.

Authors:  Pascal Kahlem; Stuart J Newfeld
Journal:  Development       Date:  2009-11       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.